Loading…

Gold nanoparticle biodistribution in pregnant mice following intravenous administration varies with gestational age

The use of nanoparticles (NPs) to deliver therapeutics to reproductive organs is an emerging approach to safely and effectively treat mothers and babies facing pregnancy complications. This study investigates the biodistribution of two different sized gold-based NPs in pregnant mice following system...

Full description

Saved in:
Bibliographic Details
Published in:Nanomedicine 2021-08, Vol.36, p.102412-102412, Article 102412
Main Authors: Irvin-Choy, N'Dea S., Nelson, Katherine M., Dang, Megan N., Gleghorn, Jason P., Day, Emily S.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The use of nanoparticles (NPs) to deliver therapeutics to reproductive organs is an emerging approach to safely and effectively treat mothers and babies facing pregnancy complications. This study investigates the biodistribution of two different sized gold-based NPs in pregnant mice following systemic delivery as a function of gestational age. Poly(ethylene glycol)-coated 15 nm gold nanoparticles or 150 nm diameter silica core/gold nanoshells were intravenously administered to pregnant mice at gestational days (E)9.5 or 14.5. NP distribution was analyzed twenty-four hours later by inductively coupled plasma-mass spectrometry and silver staining of histological specimens. More NPs accumulated in placentas than embryos and delivery to these tissues was greater at E9.5 than E14.5. Neither NP type affected fetal weight or placental weight, indicating minimal short-term toxicity in early to mid-stage pregnancy. These findings warrant continued development of NPs as tools to deliver therapeutics to reproductive tissues safely. Nanoparticle delivery to placentas and embryos in pregnant mice following systemic administration is gestation dependent. Additionally, systemically delivered nanoparticles do not alter fetal weight, placental weight, or maternal organ pathology, indicating that nanomedicine has promise to advance the treatment of maternal–fetal disorders. [Display omitted]
ISSN:1549-9634
1549-9642
DOI:10.1016/j.nano.2021.102412